Certain Starches May Decrease Risk of Cancer From Red Meat
the Cancer Therapy Advisor take:
According to a new study published in the journal Cancer Prevention Research, some starches lower the risk of developing cancer caused by consuming substantial amounts of red meat. Karen J. Humphreys, PhD, of the Flinders Center for Innovation in Cancer at Flinders University in Adelaide, Australia, and lead investigator studied the effects of eating a diet composed of large amounts of red meat and resistant starches.
The control group consumed 300 grams of lean red meat daily while the intervention group ate that plus butyrylated high amylose maize starch for 4 weeks. Resistant starches are found in lentils, chickpeas, cooled potatoes, whole grains, slightly green bananas, seeds, and beans.
Gut bacteria ferment these starches to produce butyrate. Levels of miR17-92 cluster miRNAs and miR21, oncogenic microRNAs, and cell proliferation were increased in rectal tissue samples whereas the miR17-92 levels were at baseline in the protective starch group. Increased levels of butyrate were found in the starch group.
Consuming large amounts of red meat is associated with an increased risk of colon cancer; however, eating starches that can confer the beneficial compound butyrate may be a simple approach to reducing the risk of developing cancers linked to the consumption of large amounts of red meat.
Eating large amounts of red meat is linked to a higher risk of colon cancer.
When only the red meat was eaten, levels of cancer-causing microRNAs were elevated in rectal tissue, as was cellular proliferation.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Opinion: Understanding the FDA's Take on Cannabidiol
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk